Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2007-11-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 300
- Registration Number
- NCT00348738
- Locations
- 🇦🇹
Department of Radiotherapy-University Hospital of Salzburg, Salzburg, Austria
🇦🇹Department of Radiotherapy-University Hospital of Innsbruck, Innsbruck, Austria
🇦🇹Department of Radiotherapy and Radiobiology-Medical University of Vienna, Vienna, Austria
REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 6
- Registration Number
- NCT00319150
- Locations
- 🇨🇦
Foothills Hospital, Calgary, Alberta, Canada
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦Humber River Regional Hosptial, Toronto, Ontario, Canada
Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 50
- Registration Number
- NCT00273767
- Locations
- 🇫🇷
Cardiac Surgery Department - CHU de Grenoble, Grenoble, France
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-04-21
- Target Recruit Count
- 192
- Registration Number
- NCT00210626
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2010-08-02
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 92
- Registration Number
- NCT00157300
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱Other transplantation centers, To Be Determined, Netherlands
Erythropoietin in Acute Myocardial Infarction
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2005-09-08
- Lead Sponsor
- Hammersmith Hospitals NHS Trust
- Target Recruit Count
- 124
- Registration Number
- NCT00149058
- Locations
- 🇬🇧
Hammersmith Hospital NHS Trust, London, United Kingdom
🇬🇧King's College London, London, United Kingdom
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 718
- Registration Number
- NCT00111137
A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia
- Conditions
- Interventions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1228
- Registration Number
- NCT00090753
Anemia in Patients With a Non-Myeloid Malignancy
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 707
- Registration Number
- NCT00038064
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.